NO20085417L - Krystallinske former av 11beta-(4-acetylfenyl)-20,20,21,21,21-pentafluor-17-hydroksy-19-nor-17alfa-pregna-4,9-dien-3-on - Google Patents

Krystallinske former av 11beta-(4-acetylfenyl)-20,20,21,21,21-pentafluor-17-hydroksy-19-nor-17alfa-pregna-4,9-dien-3-on

Info

Publication number
NO20085417L
NO20085417L NO20085417A NO20085417A NO20085417L NO 20085417 L NO20085417 L NO 20085417L NO 20085417 A NO20085417 A NO 20085417A NO 20085417 A NO20085417 A NO 20085417A NO 20085417 L NO20085417 L NO 20085417L
Authority
NO
Norway
Prior art keywords
pregna
pentafluoro
dien
hydroxy
acetylphenyl
Prior art date
Application number
NO20085417A
Other languages
English (en)
Inventor
Gabriele Winter
Wolfgang Beckmann
Edda Kramer
Thomas Ginko
Evelin Amoulong
Arwed Cleve
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20085417L publication Critical patent/NO20085417L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse gjelder krystallinske former av lip- (4- acetylfenyl)-20,20,21,21,21-penta- fluor-17-hydroksy-19-nor-17a- pregna-4,9-dien-3-on. Nærmere be- stemt gj elder oppfinnelsen to krystallinske ansolvat/anhydrat- former av denne forbindelsen, de polymorfe formene I og II. Fore- liggende oppfinnelse gjelder imid- lertid også krystallinske solvater, f.eks. metanol- og etanolsolvater av lip-(4-acetylfenyl) - 20,20,21,21,21-pentafluor-17-hydroksy-19-nor-17a-pregna-4, 9-dien-3-on som forløpere for fremstilling av de to polymorfe formene I og II. Fremgangsmåter beskrives for fremstilling av den polymorfe form I ved hjelp av fortrengnings-krystallisering eller ved hj elp av ekstraksjon. Valget av det siste løsemidlet før dannelsen av ansol-vatet kan utføres basert på f or-skjellene i de enkelte solvaters rensningsforhold for lip-(4-acetyl-fenyl)-20,20,21,21,21-pentafluor-17-hydroksy-19-nor-17a-pregna-4,9-dien-3-on. Den polymorfe form I ifølge oppfinnelsen er spesielt egnet for fremstilling av legemidler .
NO20085417A 2006-06-02 2008-12-30 Krystallinske former av 11beta-(4-acetylfenyl)-20,20,21,21,21-pentafluor-17-hydroksy-19-nor-17alfa-pregna-4,9-dien-3-on NO20085417L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81012706P 2006-06-02 2006-06-02
EP06090095A EP1862468A1 (de) 2006-06-02 2006-06-02 Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
PCT/EP2007/004805 WO2007140917A2 (de) 2006-06-02 2007-05-31 KRISTALLINE FORMEN VON 11 ß-(4-ACETYLPHENYL)-20, 20, 21,21, 21-PENTAFLUOR-17- HYDROXY-19-NOR-17α-PREGNA-4,9-DIEN-3-ON

Publications (1)

Publication Number Publication Date
NO20085417L true NO20085417L (no) 2008-12-30

Family

ID=37562153

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085417A NO20085417L (no) 2006-06-02 2008-12-30 Krystallinske former av 11beta-(4-acetylfenyl)-20,20,21,21,21-pentafluor-17-hydroksy-19-nor-17alfa-pregna-4,9-dien-3-on

Country Status (15)

Country Link
US (1) US7910573B2 (no)
EP (2) EP1862468A1 (no)
JP (1) JP2009538855A (no)
KR (1) KR20090016008A (no)
AR (1) AR061151A1 (no)
AU (1) AU2007256432A1 (no)
BR (1) BRPI0713093A2 (no)
CA (1) CA2654126A1 (no)
EA (1) EA200802385A1 (no)
EC (1) ECSP088934A (no)
MX (1) MX2008015348A (no)
NO (1) NO20085417L (no)
TN (1) TNSN08499A1 (no)
UY (1) UY30384A1 (no)
WO (1) WO2007140917A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
US9290293B2 (en) 2013-01-03 2016-03-22 Samuel A. Tilton Storage systems and related methods
EP3701951A4 (en) * 2017-10-26 2020-09-16 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTAL SHAPE OF SELECTIVE PROGESTERONE RECEPTOR MODULATORS AND PROCESS FOR THEIR PRODUCTION

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2620707B1 (fr) * 1987-09-18 1989-12-08 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FR2644789B1 (fr) * 1989-03-22 1995-02-03 Roussel Uclaf Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
ATE172469T1 (de) 1989-08-04 1998-11-15 Schering Ag 11 beta-aryl-gona-4,9-dien-3-one
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
FR2718354B1 (fr) 1994-04-08 1996-05-03 Roussel Uclaf Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.
AU710139B2 (en) * 1996-05-01 1999-09-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The 21-substituted progesterone derivatives as new antiprogestational agents
FR2757400B1 (fr) 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
JPH11171774A (ja) 1997-12-05 1999-06-29 Kyowa Hakko Kogyo Co Ltd 血球増多剤
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
WO1999053924A1 (en) 1998-04-17 1999-10-28 Kyowa Hakko Kogyo Co., Ltd. Analgetic agent
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
SI1325022T1 (sl) * 2000-09-18 2007-04-30 Applied Research Systems Metoda za pripravo 21-hidroksi-6,19-oksidoprogesterona (21oh-6op)
DE10051609A1 (de) * 2000-10-18 2002-05-02 Schering Ag Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
DE10221034A1 (de) * 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US8865200B2 (en) 2004-07-09 2014-10-21 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
US20070105828A1 (en) * 2005-08-19 2007-05-10 Glenmark Pharmaceuticals Limited Novel polymorph form M of mifepristone and process for its preparation

Also Published As

Publication number Publication date
US20080085875A1 (en) 2008-04-10
JP2009538855A (ja) 2009-11-12
MX2008015348A (es) 2008-12-17
TNSN08499A1 (en) 2010-04-14
KR20090016008A (ko) 2009-02-12
BRPI0713093A2 (pt) 2012-10-16
ECSP088934A (es) 2009-01-30
US7910573B2 (en) 2011-03-22
EA200802385A1 (ru) 2009-06-30
UY30384A1 (es) 2008-03-31
AU2007256432A1 (en) 2007-12-13
WO2007140917A2 (de) 2007-12-13
AR061151A1 (es) 2008-08-06
WO2007140917A3 (de) 2008-04-10
CA2654126A1 (en) 2007-12-13
EP2024383A2 (de) 2009-02-18
EP1862468A1 (de) 2007-12-05

Similar Documents

Publication Publication Date Title
NO20085417L (no) Krystallinske former av 11beta-(4-acetylfenyl)-20,20,21,21,21-pentafluor-17-hydroksy-19-nor-17alfa-pregna-4,9-dien-3-on
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
WO2009053854A3 (en) Polymorphs of dasatinib and process for preparation thereof
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EP4282482A3 (en) Nucleoside phosphoramidate prodrugs
BRPI0516911A (pt) método para a preparação de um composto e composto de anilina
MX2009013591A (es) Proceso para la preparacion de pirazoles.
TW200612948A (en) 2-substituted heteroaryl compounds
WO2006072393A3 (de) Sulfonylpyrrolidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EA201290334A1 (ru) Способы синтеза и очистки дезоксихолевой кислоты
EA201100517A1 (ru) Способ получения дабигатрана и его промежуточные соединения
NO20081621L (no) Tetrahydrokinoliner, syntese og intermediater
JO2749B1 (en) Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application
NO20085359L (no) Fremgangsmate for fremstilling av renset hydrokinon
WO2008101247A3 (en) 6 ' substituted indole and indazole derivatives having 5-ht6 receptor affinity
NO20081617L (no) Metoder for fremstilling av Glutaminsyrederivater
EA200870606A1 (ru) Серосодержащие производные пиразола в качестве избирательных антагонистов рецептора каннабиноидов св
UA100862C2 (ru) Шестичленные ароматические соединения, их получение и применение (варианты)
WO2009021943A3 (de) Neues herstellverfahren
BR112014006844A2 (pt) composições e métodos relacionados ao ácido deoxicólico e seus polimorfos
WO2006112742A3 (en) PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2α DERIVATIVES
MX2010003056A (es) Polimorfos de valomaciclovir.
DK1877370T3 (da) Fremgangsmåde til fremstilling af hydrazon-derivater
WO2006131338A3 (en) Crystalline solvate of omeprazole sodium
MX2008000011A (es) Procesos para preparar derivados de pirazol-o-glucosido y nuevos intermediarios de dichos procesos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application